LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

Inicio・Lista de Acciones・Anavex Life Sciences Corp

Anavex Life Sciences Corp

Cerrado

SectorSanidad

2.71 1.5

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

2.66

Máximo

2.73

Métricas clave
By Trading Economics
Ingresos	4.1M -5.7M
Empleados	34
EBITDA	3.1M -6.8M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+594.44% upside

Dividendos
By Dow Jones
Próximas Ganancias	26 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-122M 267M
Apertura anterior	1.21
Cierre anterior	2.71

Noticias sobre sentimiento de mercado

By Acuity

50%

159 / 345 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

8.275 / 9.312 Soporte y Resistencia

Anavex Life Sciences Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

20 may 2026, 23:31 UTC

Acciones populares

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

20 may 2026, 22:52 UTC

Principales Movimientos del Mercado

Osisko Shares Fall on Planned Convertible Notes Offering

20 may 2026, 23:47 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

20 may 2026, 23:47 UTC

Charlas de Mercado

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

20 may 2026, 23:44 UTC

Ganancias

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

20 may 2026, 23:35 UTC

Charlas de Mercado

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

20 may 2026, 23:30 UTC

Charlas de Mercado

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

20 may 2026, 23:17 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

20 may 2026, 23:17 UTC

Charlas de Mercado

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

20 may 2026, 23:15 UTC

Charlas de Mercado

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

20 may 2026, 23:14 UTC

Ganancias

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

20 may 2026, 23:02 UTC

Charlas de Mercado

KMD Brands Faces Two Testing Hurdles -- Market Talk

20 may 2026, 22:57 UTC

Charlas de Mercado

Infratil's Other Assets Deserve Attention, Too -- Market Talk

20 may 2026, 22:57 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

20 may 2026, 22:57 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

20 may 2026, 22:51 UTC

Charlas de Mercado

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

20 may 2026, 22:51 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

20 may 2026, 22:27 UTC

Charlas de Mercado

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

20 may 2026, 22:14 UTC

Charlas de Mercado

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

20 may 2026, 22:10 UTC

Ganancias

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

20 may 2026, 22:00 UTC

Ganancias

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

20 may 2026, 21:38 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

20 may 2026, 21:27 UTC

Ganancias

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

20 may 2026, 21:20 UTC

Ganancias

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

20 may 2026, 21:19 UTC

Ganancias

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

20 may 2026, 21:18 UTC

Ganancias

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

20 may 2026, 21:17 UTC

Ganancias

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

20 may 2026, 21:17 UTC

Ganancias

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

20 may 2026, 21:17 UTC

Ganancias

Nvidia's Vera CPU Opens New $200B Market, CFO Says

20 may 2026, 21:16 UTC

Ganancias

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Comparación entre iguales

Cambio de precio

Anavex Life Sciences Corp previsión

Precio Objetivo

By TipRanks

594.44% repunte

Estimación a 12 Meses

Media 20 USD 594.44%

Máximo 20 USD

Mínimo 20 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Anavex Life Sciences Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

Comprar

Mantener

Vender

De acuerdo con 2 analistas que ofrecen calificaciones bursátiles a para Anavex Life Sciences Corp Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

8.275 / 9.312Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentimiento

By Acuity

159 / 345 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.